MA50402A - Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 - Google Patents
Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1Info
- Publication number
- MA50402A MA50402A MA050402A MA50402A MA50402A MA 50402 A MA50402 A MA 50402A MA 050402 A MA050402 A MA 050402A MA 50402 A MA50402 A MA 50402A MA 50402 A MA50402 A MA 50402A
- Authority
- MA
- Morocco
- Prior art keywords
- muscarinic
- receptor
- compounds used
- positive allosteric
- allosteric modulators
- Prior art date
Links
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title 1
- 230000003281 allosteric effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741037090 | 2017-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50402A true MA50402A (fr) | 2021-05-19 |
Family
ID=64277732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050402A MA50402A (fr) | 2017-10-18 | 2018-10-17 | Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11234979B2 (fr) |
| EP (1) | EP3697790B1 (fr) |
| JP (1) | JP7104783B2 (fr) |
| KR (1) | KR102438588B1 (fr) |
| CN (1) | CN111212840B (fr) |
| AU (1) | AU2018353544B2 (fr) |
| BR (1) | BR112020007606A2 (fr) |
| CA (1) | CA3076757C (fr) |
| EA (1) | EA039781B1 (fr) |
| IL (1) | IL273748B (fr) |
| MA (1) | MA50402A (fr) |
| MX (1) | MX2020003832A (fr) |
| NZ (1) | NZ764004A (fr) |
| SG (1) | SG11202003284RA (fr) |
| WO (1) | WO2019077517A1 (fr) |
| ZA (1) | ZA202002034B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ763341A (en) * | 2017-10-27 | 2023-03-31 | Suven Life Sciences Ltd | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators |
| MX2021004471A (es) * | 2018-10-17 | 2021-08-24 | Suven Life Sciences Ltd | Derivados de pirrolo-pididazina como moduladores alostéricos positivos del receptor muscarínico m1. |
| KR102765208B1 (ko) * | 2021-08-10 | 2025-02-11 | 연세대학교 산학협력단 | 1,3-치환된 인돌리진의 원팟 합성 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754220B2 (en) | 2009-11-20 | 2014-06-17 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide M1 receptor positive allosteric modulators |
| TW201512197A (zh) * | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| MX2016001942A (es) * | 2013-09-27 | 2016-06-02 | Hoffmann La Roche | Derivados de indol e indazol. |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| WO2016172547A1 (fr) | 2015-04-24 | 2016-10-27 | Vanderbilt University | Analogues d'imidazopyridine et de triazolopyridine substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 |
| SMT201900213T1 (it) | 2015-06-08 | 2019-05-10 | Suven Life Sciences Ltd | Modulatori allosterici positivi del recettore muscarinico m1 |
| EP3347349B1 (fr) | 2015-09-10 | 2019-09-18 | Suven Life Sciences Limited | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
-
2018
- 2018-10-17 WO PCT/IB2018/058047 patent/WO2019077517A1/fr not_active Ceased
- 2018-10-17 BR BR112020007606-6A patent/BR112020007606A2/pt unknown
- 2018-10-17 CN CN201880066720.4A patent/CN111212840B/zh active Active
- 2018-10-17 SG SG11202003284RA patent/SG11202003284RA/en unknown
- 2018-10-17 JP JP2020520490A patent/JP7104783B2/ja active Active
- 2018-10-17 MA MA050402A patent/MA50402A/fr unknown
- 2018-10-17 EP EP18801031.8A patent/EP3697790B1/fr active Active
- 2018-10-17 US US16/753,183 patent/US11234979B2/en active Active
- 2018-10-17 EA EA202090925A patent/EA039781B1/ru unknown
- 2018-10-17 MX MX2020003832A patent/MX2020003832A/es unknown
- 2018-10-17 KR KR1020207013222A patent/KR102438588B1/ko active Active
- 2018-10-17 CA CA3076757A patent/CA3076757C/fr active Active
- 2018-10-17 NZ NZ764004A patent/NZ764004A/en unknown
- 2018-10-17 AU AU2018353544A patent/AU2018353544B2/en active Active
-
2020
- 2020-04-01 IL IL273748A patent/IL273748B/en unknown
- 2020-05-04 ZA ZA2020/02034A patent/ZA202002034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7104783B2 (ja) | 2022-07-21 |
| WO2019077517A1 (fr) | 2019-04-25 |
| CN111212840A (zh) | 2020-05-29 |
| KR20200069330A (ko) | 2020-06-16 |
| US20200237761A1 (en) | 2020-07-30 |
| EA202090925A1 (ru) | 2020-07-13 |
| CA3076757C (fr) | 2022-10-11 |
| EP3697790B1 (fr) | 2023-01-18 |
| EA039781B1 (ru) | 2022-03-14 |
| IL273748B (en) | 2022-06-01 |
| AU2018353544B2 (en) | 2020-09-17 |
| CA3076757A1 (fr) | 2019-04-25 |
| CN111212840B (zh) | 2022-07-22 |
| EP3697790A1 (fr) | 2020-08-26 |
| NZ764004A (en) | 2023-03-31 |
| US11234979B2 (en) | 2022-02-01 |
| MX2020003832A (es) | 2020-08-06 |
| JP2021500323A (ja) | 2021-01-07 |
| ZA202002034B (en) | 2021-05-26 |
| IL273748A (en) | 2020-05-31 |
| SG11202003284RA (en) | 2020-05-28 |
| AU2018353544A1 (en) | 2020-04-16 |
| BR112020007606A2 (pt) | 2020-09-29 |
| KR102438588B1 (ko) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54169A (fr) | Tolyles substitués utilisés en tant que fongicides | |
| EP3356356A4 (fr) | Composés utiles en tant que modulateurs de trpm8 | |
| EP3802467A4 (fr) | Composés spirocycliques | |
| LT3864003T (lt) | Integruoto streso mechanizmo provaistų moduliatoriai | |
| EP3781156A4 (fr) | Composés spirocycliques | |
| MA49128A (fr) | Dérivés de pyrimidine utilisés en tant que modulateurs des récepteurs des pge2 | |
| MA49888A (fr) | Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1 | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| HUE053586T2 (hu) | Muszkarin M1 receptor pozitív alloszterikus modulátorok | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| DK3474846T3 (da) | Positive, allosteriske modulatorer af den muskarinske acetylcholinreceptor m4 | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| HUE054009T2 (hu) | Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| DK3433234T3 (da) | Allosteriske modulatorer af nicotinacetylcholinreceptorer | |
| MA44253A (fr) | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m1 | |
| MA49126A (fr) | Dérivés de phényle utilisés en tant que modulateurs des récepteurs des pge2 | |
| EP3509588A4 (fr) | Composés bicycliques utiles en tant que modulateurs du gpr120 | |
| EP3558307A4 (fr) | Modulateurs allostériques d'éther de pipéridine d'hétéroaryle 6,6-fusionné du récepteur muscarinique m4 de l'acétylcholine | |
| IL283967A (en) | Modulators of hsd17b13 expression | |
| EP2958564A4 (fr) | Composés hétéro-aromatiques en tant que modulateurs de pi3 kinase | |
| MA46722A (fr) | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 | |
| EP3820530A4 (fr) | Formulation de composés cannabinoïdes | |
| MA44772A (fr) | 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t | |
| MA52286A (fr) | Dérivés de pyrazo-tétrahydroisoquinoléine en tant que modulateurs positifs du récepteur d1 de la dopamine |